AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal survival
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge
Number of subjects: 14
Study 32028921 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone distribution program with overdose prevention education
Number of subjects: 2000
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of targeted postsurgical systemic antibiotic therapy for implant-free SIs
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of targeted postsurgical systemic antibiotic therapy for implant-related SIs
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant multidisciplinary care (surgical, re-educational, internist, and infectious disease)
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome of remission
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events of antibiotic therapy
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in nutritional status
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of immune suppression
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Total costs
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional scores
Number of subjects: 236
Study 32028985 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely evolution of surgical wounds
Number of subjects: 236
Study 32028991 — intervention group
Group type: EXPERIMENTAL
Intervention: HepaStem (liver-derived mesenchymal stem cells) with anticoagulants (heparin and bivalirudin)
Number of subjects: 11
Study 32028991 — intervention group
Group type: COMPARATOR
Intervention: HepaStem (liver-derived mesenchymal stem cells)
Number of subjects: 11
Study 32028998 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study
Number of subjects: 0
Study 32028998 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 32029070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-induced sleep
Number of subjects: 21
Study 32029070 — intervention group
Group type: COMPARATOR
Intervention: Propofol-induced sleep (DISE)
Number of subjects: 21
Study 32029130 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcal endocarditis (EE)
Number of subjects: 516
Study 32029130 — intervention group
Group type: COMPARATOR
Intervention: Nonenterococcal endocarditis (NEE)
Number of subjects: 516
Study 32029139 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Microcirculatory Resistance
Number of subjects: 0
Study 32029139 — intervention group
Group type: COMPARATOR
Intervention: Serum biomarkers
Number of subjects: 0
Study 32029254 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1580
Study 32029254 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1580
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD-scan
Number of subjects: 305
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse palpation
Number of subjects: 305
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible handheld Doppler
Number of subjects: 305
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Brachial Pressure Index
Number of subjects: 305
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe Brachial Pressure Index
Number of subjects: 305
Study 32029491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous pressure of oxygen
Number of subjects: 305
Study 32029491 — intervention group
Group type: COMPARATOR
Intervention: Full lower limb arterial DUS
Number of subjects: 305
Study 32030422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g three times daily for 24-72 hours followed by 5 g once daily for ≤12 months
Number of subjects: 751
Study 32030422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g once daily during maintenance phase (MP)
Number of subjects: 751
Study 32030422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 751
Study 32030422 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) during maintenance phase (MP)
Number of subjects: 751
Study 32030595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic Medication Management Fidelity Scale
Number of subjects: 8
Study 32031433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Breast Exam (iBE)
Number of subjects: 486
Study 32031433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Breast Examination (CBE)
Number of subjects: 486
Study 32031433 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 486
Study 32031542 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT + AOT
Number of subjects: 44
Study 32031542 — intervention group
Group type: COMPARATOR
Intervention: CIMT
Number of subjects: 44
Study 32031643 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphones
Number of subjects: 0
Study 32031643 — intervention group
Group type: COMPARATOR
Intervention: Wearable Devices
Number of subjects: 0
Study 32031690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasomodulator Therapy
Number of subjects: 0
Study 32031690 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32031693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib at a dose of 24 mg/day
Number of subjects: 28
Study 32031758 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic guided heart failure management using a small pressure sensor implanted in the pulmonary artery (PA)
Number of subjects: 800
Study 32031870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 1432
Study 32031870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring graft
Number of subjects: 1432
Study 32031870 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1432
Study 32032174 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter) for 5-35 days
Number of subjects: 19
Study 32032174 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin followed by optional fluconazole
Number of subjects: 19
Study 32032309 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccine against diphtheria
Number of subjects: 0
Study 32032671 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 156
Study 32032671 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 156
Study 32032901 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation (median AI 5.4%, IQR:2.9-9.1)
Number of subjects: 103
Study 32032901 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation (median AI 2%, IQR:0.6-4.9)
Number of subjects: 103
Study 32032901 — intervention group
Group type: EXPERIMENTAL
Intervention: AI≥10%
Number of subjects: 103
Study 32032901 — intervention group
Group type: EXPERIMENTAL
Intervention: AI<10%
Number of subjects: 103
Study 32032901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic PEEP
Number of subjects: 103
Study 32032901 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Acute Physiology Score 3
Number of subjects: 103
Study 32033600 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg slow-release misoprostol vaginal insert
Number of subjects: 0
Study 32033600 — intervention group
Group type: COMPARATOR
Intervention: 25 mcg oral misoprostol tablets
Number of subjects: 0
Study 32033617 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRM-CRT (Mixed Model for Repeated Measures for Cluster Randomized Trials)
Number of subjects: 0
Study 32033617 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRM-CRT
Number of subjects: 0
Study 32034017 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) with beta-blockers and RAS inhibitors
Number of subjects: 2045
Study 32034017 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers only
Number of subjects: 2045
Study 32034017 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors only
Number of subjects: 2045
Study 32034017 — intervention group
Group type: COMPARATOR
Intervention: No GDMT
Number of subjects: 2045
Study 32034416 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy (EAT) for PTSD, administered in an eight-session group protocol.
Number of subjects: 2
Study 32034419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile GnRH administration to 2 GnRH-deficient patients
Number of subjects: 51
Study 32034419 — intervention group
Group type: COMPARATOR
Intervention: Clinical and biochemical assessment of male patients
Number of subjects: 51
Study 32034419 — intervention group
Group type: COMPARATOR
Intervention: Clinical and biochemical assessment of female patients
Number of subjects: 51
Study 32034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 175 mg bid for 2.5 days with carboplatin alone or paclitaxel plus carboplatin
Number of subjects: 19
Study 32034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 225 mg bid in combination with paclitaxel plus carboplatin
Number of subjects: 19
Study 32034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 175 mg bid for 2.5 days
Number of subjects: 19
Study 32034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib
Number of subjects: 19
Study 32035303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruxers (BEI ≥ 2)
Number of subjects: 0
Study 32035303 — intervention group
Group type: COMPARATOR
Intervention: Non-bruxers (BEI < 2)
Number of subjects: 0
Study 32035303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic types of electromyographical pathways
Number of subjects: 0
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (preserved ejection fraction)
Number of subjects: 150
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (mid-range ejection fraction)
Number of subjects: 150
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (reduced ejection fraction)
Number of subjects: 150
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II and III
Number of subjects: 150
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: RV systolic dysfunction
Number of subjects: 150
Study 32035524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-range ejection fraction
Number of subjects: 150
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessment at RASS = 0
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessment at RASS = -1
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessment at RASS = -2
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessment at RASS = -3
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDSC assessment at RASS = 0
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDSC assessment at RASS = -1
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDSC assessment at RASS = -2
Number of subjects: 1660
Study 32035691 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDSC assessment at RASS = -3
Number of subjects: 1660
Study 32035691 — intervention group
Group type: COMPARATOR
Intervention: CAM-ICU vs ICDSC at RASS = -3
Number of subjects: 1660
Study 32035691 — intervention group
Group type: COMPARATOR
Intervention: CAM-ICU vs ICDSC at RASS = 0
Number of subjects: 1660
Study 32035691 — intervention group
Group type: COMPARATOR
Intervention: CAM-ICU vs ICDSC at RASS = -1 or -2
Number of subjects: 1660
Study 32035752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse and primed constant infusion of multiple stable tracers of amino acids
Number of subjects: 23
Study 32035772 — intervention group
Group type: EXPERIMENTAL
Intervention: A+/P+ (n = 77)
Number of subjects: 333
Study 32035772 — intervention group
Group type: EXPERIMENTAL
Intervention: A+/P- (n = 54)
Number of subjects: 333
Study 32035772 — intervention group
Group type: EXPERIMENTAL
Intervention: A-/P+ (n = 71)
Number of subjects: 333
Study 32035772 — intervention group
Group type: EXPERIMENTAL
Intervention: A-/P- (n = 131)
Number of subjects: 333
Study 32036486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-induced platelet aggregation in OSA subjects with ODI ≥ 15
Number of subjects: 31
Study 32036486 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-induced platelet aggregation in OSA subjects with ODI ≥ 15
Number of subjects: 31
Study 32036486 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40L platelet surface expression in OSA subjects with ODI ≥ 15
Number of subjects: 31
Study 32036486 — intervention group
Group type: COMPARATOR
Intervention: Platelet responses to other agonists, CD62P platelet surface expression, and PMA levels
Number of subjects: 31
Study 32036499 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI ratio at the end of SBT
Number of subjects: 44
Study 32036499 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PPI during SBT
Number of subjects: 44
Study 32036499 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI augmentation during SBT
Number of subjects: 44
Study 32036499 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of augmenting PPI by 41% at the end of SBT
Number of subjects: 44
Study 32036553 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) - a motivational interviewing intervention
Number of subjects: 365
Study 32036553 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 365
Study 32037403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib (1 mg per os once daily, 21 days on-7 days off)
Number of subjects: 27
Study 32037699 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversense CGM System (180-day implantable glucose sensor)
Number of subjects: 100
Study 32038326 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 59
Study 32038326 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Number of subjects: 59
Study 32038463 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care at certified primary stroke centers
Number of subjects: 0
Study 32038463 — intervention group
Group type: COMPARATOR
Intervention: Quality of care at never-certified hospitals
Number of subjects: 0
Study 32038751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidose-isotretinoin administered without food
Number of subjects: 0
Study 32038757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarecycline
Number of subjects: 0
Study 32038757 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32039174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvis-Thorax Coordination
Number of subjects: 0
Study 32039215 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 213
Study 32039215 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 213
Study 32039215 — intervention group
Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 213
Study 32039263 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived stem cells (BMSC)
Number of subjects: 6
Study 32039263 — intervention group
Group type: COMPARATOR
Intervention: Natural history of the disease (as comparator)
Number of subjects: 6
Study 32040232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal complaints (measured by IBS-SSS)
Number of subjects: 30
Study 32040232 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization
Number of subjects: 30
Study 32040232 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IBS-SSS scores
Number of subjects: 30
Study 32040549 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-64407564 (GPRC5DxCD3 bispecific antibody)
Number of subjects: 0
Study 32040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5 mg/day titrated to a maximum daily dose of 2.5 mg)
Number of subjects: 26
Study 32040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline reward learning
Number of subjects: 26
Study 32040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prediction error signalling
Number of subjects: 26
Study 32040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline D2/3 receptor availability
Number of subjects: 26
Study 32040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dopamine release
Number of subjects: 26
Study 32040562 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 26)
Number of subjects: 26
Study 32040573 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum miR-622 expression prior to first-line platinum-based chemotherapy
Number of subjects: 0
Study 32040573 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum miR-622 expression in the BRC cohort
Number of subjects: 0
Study 32040573 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum miR-622 expression at relapse
Number of subjects: 0
Study 32040611 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG quantification using EARL standardized PET acquisitions and reconstruction
Number of subjects: 124
Study 32040785 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 20
Study 32040785 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 20
Study 32041862 — intervention group
Group type: EXPERIMENTAL
Intervention: WZTL-002 (third-generation anti-CD19 CAR T-cells)
Number of subjects: 0
Study 32041862 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (intravenous fludarabine and cyclophosphamide)
Number of subjects: 0
Study 32042283 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH (SC) 40 IU/kg or 60 IU/kg twice weekly for 52 to 140 weeks
Number of subjects: 76
Study 32042283 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH (SC) during the first trimester
Number of subjects: 76
Study 32043771 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo patients receiving first-line regimens containing chemotherapy (89.7%), trastuzumab (95.7%), and pertuzumab (77.8%)
Number of subjects: 977
Study 32043771 — intervention group
Group type: COMPARATOR
Intervention: Recurrent patients receiving first-line regimens containing chemotherapy (80.0%), trastuzumab (85.9%), and pertuzumab (68.6%)
Number of subjects: 977
Study 32043771 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo patients
Number of subjects: 977
Study 32043771 — intervention group
Group type: COMPARATOR
Intervention: Recurrent patients
Number of subjects: 977
Study 32043777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg twice daily, with dose increases to 10 mg twice daily permitted after 3 days in the absence of toxicity)
Number of subjects: 49
Study 32043777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 49
Study 32043778 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperAcute Renal (HAR) immunotherapy
Number of subjects: 18
Study 32043778 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperAcute Renal (HAR) immunotherapy (low-dose)
Number of subjects: 18
Study 32043778 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperAcute Renal (HAR) immunotherapy (high-dose)
Number of subjects: 18
Study 32043962 — intervention group
Group type: EXPERIMENTAL
Intervention: AASM criteria for OSA
Number of subjects: 248
Study 32043962 — intervention group
Group type: COMPARATOR
Intervention: CMS criteria for OSA
Number of subjects: 248
Study 32043962 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant group (AASM positive, CMS negative)
Number of subjects: 248
Study 32043962 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index ≥ 15 events/h
Number of subjects: 248
Study 32044171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 5
Study 32044400 — intervention group
Group type: EXPERIMENTAL
Intervention: Remestemcel-L (human mesenchymal stromal cells) administered as 8 biweekly intravenous infusions.
Number of subjects: 241
Study 32044401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 128
Study 32044754 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth HIV prevention toolkit intervention
Number of subjects: 149
Study 32044754 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 149
Study 32045475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 111
Study 32045583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose enoxaparin 40 mg daily
Number of subjects: 131
Study 32045583 — intervention group
Group type: COMPARATOR
Intervention: Weight-tiered enoxaparin (30 mg daily for <70 kg, 40 mg daily for 70-89.9 kg, 50 mg daily for ≥90 kg)
Number of subjects: 131
Study 32046348 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype of the rs699947 variant
Number of subjects: 357
Study 32046348 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight controls
Number of subjects: 357
Study 32046663 — intervention group
Group type: EXPERIMENTAL
Intervention: activPAL3 micro (criterion)
Number of subjects: 58
Study 32046663 — intervention group
Group type: COMPARATOR
Intervention: waist-worn Actigraph GT3X
Number of subjects: 58
Study 32046663 — intervention group
Group type: COMPARATOR
Intervention: self-report questionnaires (PPAQ and SB2D)
Number of subjects: 58
Study 32046663 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2D
Number of subjects: 58
Study 32046725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) + Oral antibiotics (OA)
Number of subjects: 0
Study 32046725 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 0